Rapport Therapeutics to Present at Major Healthcare Conferences
BOSTON and SAN DIEGO — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company committed to developing innovative small molecule medicines for patients with central nervous system (CNS) disorders, has announced important presentations at two upcoming investor conferences.
Details of the Presentations
The management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference, which will be held in New York City. Their presentation is scheduled for Thursday, September 5, 2024, at 4:50 pm ET. This conference is well-known for bringing together leaders in the healthcare field to discuss advancements and strategies in the industry.
In addition, Rapport Therapeutics will take part in TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit, a virtual event. Their presentation is set for Thursday, September 26, 2024, at 11:40 am ET. This summit highlights the latest developments in neuropsychiatry and emerging treatment paradigms.
About Rapport Therapeutics
Rapport Therapeutics is dedicated to discovering and developing groundbreaking precision neuromedicines designed for individuals suffering from CNS disorders. The founders' expertise, recognized for their pioneering work on receptor associated proteins (RAPs) in the brain, is fundamental to Rapport’s innovative RAP technology platform.
This platform provides the groundwork for a novel approach to developing precision small molecule candidates, potentially overcoming many challenges typically encountered in traditional neurology drug discovery processes. Currently, Rapport is advancing its lead clinical program, RAP-219, which emphasizes neuroanatomical specificity by targeting RAPs expressed only in select brain regions.
Current Clinical Trials and Research Endeavors
RAP-219 is currently undergoing clinical trials aimed at treating a range of conditions, including focal epilepsy, peripheral neuropathic pain, and bipolar disorder. This focused pipeline reflects Rapport’s dedication to finding effective solutions for complex CNS disorders. Additionally, the company is actively advancing other preclinical and late-stage discovery programs that address chronic pain and hearing disorders.
Connecting with Rapport Therapeutics
For inquiries and more information, individuals can reach out to Rapport Therapeutics through their Head of Communications & IR, Julie DiCarlo, via email at jdicarlo@rapportrx.com. The company is committed to maintaining transparency with its stakeholders and the broader community by providing regular updates on their progress and insights into their research efforts.
Frequently Asked Questions
What is Rapport Therapeutics focused on?
Rapport Therapeutics primarily focuses on the discovery and development of innovative small molecule medicines targeting CNS disorders.
When and where will the presentations take place?
The company will present at two conferences: the Morgan Stanley Conference on September 5, 2024, and TD Cowen's Summit on September 26, 2024.
What is the significance of RAP-219?
RAP-219 is the lead clinical program that aims for targeted delivery of treatments to specific regions in the brain, offering hope for various neurological conditions.
How can I learn more about the company’s progress?
Interested individuals can visit the company’s website or contact their Head of Communications for the latest information on their initiatives and developments.
How does RAP technology benefit drug discovery?
The RAP technology platform allows for a unique approach in generating precision small molecule candidates, potentially overcoming the limitations of traditional drug discovery methods in neurology.
